Apellis Pharmaceuticals and Sobi secured FDA approval for pegcetacoplan (Empaveli) to treat complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This marks the second approved treatment for C3G and the first for IC-MPGN, two severe kidney diseases with limited options. The decision follows phase III trial data demonstrating significant proteinuria reductions and kidney function stabilization. Empaveli's annual wholesale price is approximately $505,000. The expansion broadens Apellis’ rare disease franchise and underscores complement pathway targeting’s therapeutic promise.